Analogous to enzymatic inhibition, a decrease in proliferation was accompanied by a decrease in CD38+/CD43hi and CD43hi/galectin-1+ CLL cells (with high CD45 activity) when normalized to account for high patient variability in these populations (Figures 4D and 4E). The gene discussed is PTPRC; the disease is B-cell chronic lymphocytic leukemia.